StressLoC: Chronic Stress as a Risk Factor for Long COVID

Sponsor
Medical University of Graz (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05652634
Collaborator
University of Klagenfurt (Other), Wayne State University (Other)
600
23.7

Study Details

Study Description

Brief Summary

The disease caused by the pathogen SARS-CoV-2 is known as coronavirus disease with the acronym COVID-19. The acute phase of this condition typically lasts one to two weeks and usually results in a full recovery. However, in about 10-30% of those affected, the symptoms persist for more than four weeks after the onset of the disease. In this case, there is an ongoing COVID-19 illness known as long COVID. Long COVID can persist for many months and cause significant distress and limitations to those affected due to the long-term health consequences.

The causes of long COVID are still unclear and, accordingly, therapeutic measures are still insufficiently developed. It is assumed that long COVID can in principle affect anyone. Age, gender, obesity and the number of symptoms during an acute COVID-19 illness are discussed as risk factors for long COVID. Another potential risk factor for developing long COVID could be chronic stress, which has been shown to put a strain on the immune system. It is known from infections with other coronaviruses and other viral respiratory diseases that chronic stress can lead to prolonged illness and limited recovery. The aim of this study is to systematically examine chronic stress, as it existed before infection with the coronavirus, as a possible risk factor for long COVID.

For this purpose, 600 people who have been proven to be infected with SARS-CoV-2 and have developed symptoms of COVID-19 will be included in this study.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Wider research context / theoretical framework: The pathophysiology leading to symptom persistence after acute COVID-19, defining long COVID, is widely unknown. Chronic stress may be a risk factor for long COVID as it can impair immune regulation and induce exaggerated inflammatory responses. It is known to negatively influence upper respiratory infections and was found to be associated with long-term symptoms following other coronavirus infections (SARS). In addition, chronic stress is an established risk factor for unspecific functional symptoms and mental health impairment. Data on these issues are scanty, however much-needed for developing proper interventions.

    Hypotheses/research questions/objectives: The primary aim of the study is to analyze the influence of chronic stress on symptom persistence in COVID-19. The study team hypothesizes that elevated levels of pre-existing self-reported chronic stress measured at the beginning of infection predict a higher proportion of patients with symptom persistence at one month after testing positive for SARS-CoV-2 infection (primary outcome). Secondary aims are to investigate the influence of chronic stress on medium- to long-term mental health outcome. In addition, the researchers longitudinally investigate chronic stress, stress-related biomarkers and allostatic load in patients with symptom persistence as compared to recovered patients.

    Approach/methods: This is a longitudinal prospective observational study designed according to STROBE guidelines in persons newly tested positive for SARS-CoV-2 infection by qPCR with symptoms of acute COVID-19. Monitoring of COVID-19-related symptoms and symptom persistence is conducted online, by phone and in outpatient clinic visits. Pre-existing chronic stress is investigated by questionnaires on perceived stress and negative life events and by analysis of hair cortisol concentrations prior to infection. Collection of blood allows measurement of SARS-CoV-2 antibodies, stress-related biomarkers and the calculation of allostatic load. Baseline and longitudinal data collection encompasses comorbidities, regular medication, screening for anxiety, depression, acute stress symptoms, and cognitive function.

    Level of originality/innovation: This is the first study prospectively investigating chronic stress as a risk factor for long COVID and associated mental health impairment by a multimodal approach. In addition, the researchers probe for stress-related biomarkers associated with symptom persistence and also investigate the impact of protective factors, such as resilience, psychosomatic competence and social support, on symptom persistence. Two novel bio-psycho-social assessment tools contribute to the results of this study. Results of this project will lead to innovative preventive and treatment interventions targeting symptom persistence and mental health sequelae after acute COVID-19.

    Primary researchers: Christian Fazekas (PI), Nandu Goswami, Barbara Hanfstingl, Voyko Kavcic.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    600 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Chronic Stress as a Risk Factor for Long COVID
    Anticipated Study Start Date :
    Jan 10, 2023
    Anticipated Primary Completion Date :
    Dec 31, 2023
    Anticipated Study Completion Date :
    Dec 31, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Symptom persistence beyond four weeks from the onset of acute symptoms of COVID-19 (subacute/ongoing symptomatic COVID-19). [Symptom persistence at one month after having tested positive for SARS-CoV-2 infection (subacute/ongoing symptomatic COVID-19)]

      Application of the Long COVID Symptom Tool (LC-ST)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adults (>18 years); qPCR-test positive for SARS-CoV-2 infection; symptom(s) of acute COVID-19; inclusion within defined timeframe of one week after testing; data collection online, by phone and at study visits feasible
    Exclusion Criteria:
    • Insufficient knowledge of German language; lengths of hair at rear vertex less than 2 cm; pregnancy or postpartum less than 3 months; refusal to give informed consent

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Medical University of Graz
    • University of Klagenfurt
    • Wayne State University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Christian Fazekas, Second Deputy Head of the Clinical Division of Medical Psychology, Psychosomatics and Psychotherapy, Principal Investigator, Senior Scientist, Medical University of Graz
    ClinicalTrials.gov Identifier:
    NCT05652634
    Other Study ID Numbers:
    • KLI 1100-B
    First Posted:
    Dec 15, 2022
    Last Update Posted:
    Dec 19, 2022
    Last Verified:
    Dec 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Christian Fazekas, Second Deputy Head of the Clinical Division of Medical Psychology, Psychosomatics and Psychotherapy, Principal Investigator, Senior Scientist, Medical University of Graz

    Study Results

    No Results Posted as of Dec 19, 2022